In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Innovent Biologics Inc.

www.innoventbio.com/en/

Latest From Innovent Biologics Inc.

Finance Watch: BioNTech, Vir Launch IPOs But Take US Offerings To Market At A Discount

BioNTech's $150m offering, after a prior large venture capital financing, gives it the third-largest market cap for a newly public drug developer in the US. Also, Innovent raises $300m in Hong Kong offering, Heron leads US follow-ons and Five Prime restructures to save $20m annually.
Financing StartUps and SMEs

Deal Watch: Themis Leverages Measles Vector Platform In Collaboration With Merck & Co.

In its first big pharma deal, Austrian biotech will develop experimental vaccines for Merck against an undisclosed target. Innovent licenses Chinese rights to Lilly diabetes candidate, while Novartis gets option to Iconic’s preclinical ophthalmology program.

Deals Business Strategies

Trend Revising? Biotech IPOs Slow Sharply In HK While Shanghai's STAR Shines

Just one year ago, biotechs were queuing up to list in Hong Kong following a relaxation of rules, but now many are postponing plans or simply shifting away, impacted by the market's low valuations, fast-changing environment and surprisingly strong competition from a new Shanghai trading section.  

Financing China

Changes Encourage Celltrion And Nan Fung To Bet On China Biosimilars Opportunity

Despite increasing competition, Celltrion has leapt into China's growing biosimilar market through a joint venture with Nan Fung, and another draw could lie in the biologics contract manufacturing potential in the country’s developing Greater Bay Area.

China Biosimilars
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
  • Services
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Immune Disorders
  • Metabolic Disorders
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • Innovent Biologics Inc.
  • Senior Management
  • Michael Yu, PhD, Pres. & CEO
    Ronald Ede, CFO
    Qinwei Zhou, PhD, COO
    Blake Salisbury, VP, Bus. Dev.
    Min Liu, Chief Commercial Officer
  • Contact Info
  • Innovent Biologics Inc.
    Phone: 512 69566088
    168 Dongping St., Suzhou Industrial Park
    Suzhou, 215123
    China
Advertisement
Advertisement
UsernamePublicRestriction

Register